Amy Valley, vice president for Clinical Strategy and Technology Solutions at Cardinal Health, discusses challenges presented within the oncology community, and how Cardinal Health is addressing these issues.
Cost management utilization tools can overcome access barriers to care within the oncology community that often falls short with the use of prior authorization, said Amy Valley, vice president for Clinical Strategy and Technology Solutions at Cardinal Health.
Transcript
What are you the most excited about or looking forward to this year at the 2023 Community Oncology Alliance Community Oncology Conference?
It's always exciting to reconnect with colleagues. I really enjoy just seeing all the people that I've known over the years in community oncology. I'm really excited this year that we are launching a new tool called Care Exchange, which will help practices have a better understanding of total cost of care, as they're navigating value-based reimbursement programs. So, very excited to be able to share that with the attendees.
You have identified many current challenges with prior authorization in oncology care. Are you hopeful that any of the recent attention from Congress on this issue will make a difference?
I am hopeful. I think the reality though will be that it will take time. I think, ultimately, we would like the prior authorization process to be dramatically changed in order to remove the barriers to getting patients on therapy in a timely fashion. But, I think those changes will be slow.
I think that payers will hang on to that as one of the few utilization management tools that they have that they feel comfortable with and they can operate. And it's hard to drive that change.
From my perspective, we're still avidly investing in tools to help alleviate the burden of prior authorization. And especially if you think about the practices, work, staff challenges that they have right now, that anything you can do to save time and to allow the staff to overcome these administrative burdens is of high value. Because of that, we're very interested in being able to make prior authorizations not so cumbersome for them to manage. Hopefully we save them time. And we can, again get patients on therapy in a more efficient manner.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More
2 Commerce Drive
Cranbury, NJ 08512